Table 4.

Change ratio in biomarkers in patient subgroups with prior ASCVD, dyslipidaemia, and statin treatment at baseline.

Variables	Prior ASCVD			Dyslipidaemia			Statin at baseline
	Change ratio from baseline		p value	Change ratio from baseline		p value	Change ratio from baseline		p value
	Luseogliflozin group (n = 44)	Voglibose group (n = 47)		Luseogliflozin group (n = 61)	Voglibose group (n = 59)		Luseogliflozin group (n = 51)	Voglibose group (n = 53)
MDA-LDL, %	5.0 (− 3.1 to 13.8)	− 1.0 (− 9.8 to 8.5)	0.45	0.16 (− 5.6 to 6.3)	− 0.6 (− 7.8 to 7.1)	0.64	1.3 (− 5.4 to 8.5)	0.1 (− 8.3 to 9.3)	0.81
Small-dense LDL cholesterol, %	− 0.3 (− 7.8 to 7.8)	− 5.3 (− 15 to 5.5)	0.43	− 1.7 (− 7.4 to 4.3)	− 8.6 (− 15.5 to − 1.1)	0.47	− 5.9 (− 12.4 to 1.1)	− 7.5 (− 16.6 to 2.6)	0.85
Adiponectin, %	− 1.1 (− 6.7 to 4.7)	− 6.7 (− 13.6 to 0.6)	0.43	− 1.6 (− 5.4 to 2.4)	− 4.0 (− 9.0 to 1.3)	0.29	− 0.9 (− 5.6 to 4.2)	− 6.3 (− 12.6 to 0.4)	0.19
High-sensitivity CRP, %	22.0 (− 10.8 to 66.8)	15.2 (− 24.5 to 75.9)	0.83	33.3 (3.0 to 72.4)	21.5 (− 14.3 to 72.3)	0.68	25.4 (− 5.0 to 65.6)	21.4 (− 16.5 to 76.5)	0.93
Total cholesterol, %	2.7 (− 1.7 to 7.1)	− 2.3 (− 5.8 to − 1.2)	0.22	1.6 (− 2.6 to 5.7)	− 5.3 (− 9.3 to − 1.3)	0.09	0.2 (− 3.7 to 4.1)	− 4.7 (− 10.0 to 0.6)	0.24
HDL cholesterol, %	3.5 (− 2.5 to 9.5)	− 2.1 (− 6.5 to 2.3)	0.36	2.4 (− 2.6 to 7.4)	− 4.7 (− 9.1 to − 0.3)	0.09	3.6 (− 1.2 to 8.3)	− 5.0 (− 11.3 to 1.2)	0.053
LDL cholesterol, %	5.9 (− 1.4 to 13.2)	3.5 (− 3.9 to 10.8)	0.94	16.5 (− 6.7 to 39.6)	− 1.9 (− 9.7 to 5.9)	0.14	17.2 (− 10.8 to 45.3)	− 1.4 (− 10.0 to 7.2)	0.29
Triglycerides, %	− 2.2 (− 14.1 to 11.3)	− 11.8 (− 22.1 to − 0.2)	0.25	− 1.3 (− 11.7 to 10.3)	− 8.9 (− 17.2 to 0.2)	0.44	− 8.3 (− 20.5 to 5.8)	− 9.8 (− 20.1 to 1.9)	0.77

Data are presented as the mean (95% confidence interval).

ASCVD atherosclerotic cardiovascular disease, CRP C-reactive protein, HDL high-density lipoprotein, MDA-LDL malondialdehyde low-density lipoprotein.